Genentech’s oral estrogen receptor antagonist significantly extends progression-free survival, accompanied by FDA authorization of a liquid biopsy companion diagnostic.

On November 16, 2026, the U.S. Food and Drug Administration (FDA) approved giredestrant (Wilserdly, Genentech, Inc.) in combination with everolimus for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated locally advanced or metastatic breast cancer.

The approval applies to patients whose disease has recurred during or after completion of endocrine-based adjuvant therapy or progressed following at least one endocrine-based treatment regimen in the metastatic setting.

FDA also authorized the FoundationOne Liquid CDx assay as a companion diagnostic to identify patients with ESR1 mutations who are eligible for the combination therapy.

Addressing Endocrine Resistance in Breast Cancer

Giredestrant is an orally administered estrogen receptor antagonist designed to interfere with estrogen receptor signaling, an important driver of ER-positive breast cancer. Mutations in the ESR1 gene can contribute to resistance to conventional endocrine therapies, presenting a significant treatment challenge for patients with advanced breast cancer.

The combination of giredestrant with everolimus, an inhibitor of the mammalian target of rapamycin (mTOR) pathway, provides an additional treatment option for this patient population.

Clinical Evidence Supporting Approval

The approval was supported by results from the evERA Breast Cancer clinical trial (NCT05306340), a randomized, open-label, multicenter study involving 373 adults with ER-positive, HER2-negative locally advanced or metastatic breast cancer, including 207 patients with ESR1 mutations. Participants received either giredestrant or a physician-selected endocrine therapy, consisting of exemestane, fulvestrant, or tamoxifen. Both treatment groups also received everolimus.

Among patients with ESR1 mutations, the combination demonstrated a statistically significant improvement in progression-free survival (PFS).

Efficacy Measure Giredestrant + Everolimus Physician’s Choice of Endocrine Therapy + Everolimus
Median progression-free survival

10.0 months

5.5 months

Objective response rate

27%

14%

 

 

 

 

 

 

 

The progression-free survival hazard ratio was 0.38 (95% CI: 0.27–0.54; p<0.0001), representing a 62% reduction in the hazard of disease progression or death during the study period.

Overall survival data were immature at the time of the analysis, meaning that a survival benefit has not yet been established.

Companion Diagnostic Advances Precision Oncology

An important component of the approval is the authorization of FoundationOne Liquid CDx, a blood-based companion diagnostic that analyzes circulating tumor DNA (ctDNA) to identify specific ESR1 mutations. The diagnostic was used in the evERA trial to determine patients’ ESR1 mutation status and identify the population for whom the combination therapy demonstrated clinical benefit.

The concurrent drug approval and companion diagnostic authorization illustrate the increasingly interconnected development of oncology therapeutics and molecular diagnostic technologies. Rather than selecting treatment solely on the basis of conventional breast cancer classifications, clinicians can use molecular information to identify patients who meet the approved treatment criteria.

Safety and Administration

The most common adverse reactions associated with giredestrant plus everolimus included stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis, and nausea. Laboratory abnormalities included reductions in several blood cell populations, elevated liver enzymes, electrolyte abnormalities, and increased creatinine.

Wilserdly prescribing information includes warnings and precautions concerning bradycardia and embryo-fetal toxicity. The recommended dose of giredestrant is 30 mg orally once daily, with or without food, until disease progression or unacceptable toxicity. Healthcare professionals should consult the respective prescribing information for both medications.

International Regulatory Collaboration

FDA conducted the review under Project Orbis, an initiative of the Oncology Center of Excellence that facilitates concurrent oncology product submissions and regulatory reviews among international partners. For this application, FDA collaborated with Health Canada and Israel’s Ministry of Health. Regulatory decisions in those jurisdictions may remain pending.

The review also utilized FDA’s Assessment Aid, a voluntary applicant submission intended to facilitate regulatory assessment. FDA approved the application four weeks ahead of its regulatory goal date.

Regulatory Intelligence Perspective

The approval of Wilserdly highlights several important developments in contemporary oncology product development:

  • The growing importance of targeting molecular mechanisms associated with treatment resistance.
  • The integration of therapeutic products and companion diagnostic technologies.
  • The expanding role of liquid biopsy in precision oncology, and
  • The use of international regulatory collaboration to facilitate oncology product reviews.

For pharmaceutical and medical device manufacturers, the approval also underscores the importance of coordinated therapeutic and diagnostic development strategies, including clinical evidence generation, biomarker selection, and regulatory submission planning.

While the progression-free survival results are encouraging, continued follow-up will be important to characterize overall survival outcomes and the longer-term clinical benefit of the combination.

The Wolverine Peptide Stack: What We Know

Promoted for faster healing and injury recovery, two experimental peptides are attracting growing consumer interest despite limited human clinical evidence and unresolved safety questions.The promise sounds almost too good to be true: faster recovery from injuries,...

Hims & Hers Moves Into Selling Unapproved Peptides

Telehealth company's planned expansion illustrates how quickly commercial markets are responding to changes in federal oversight of experimental therapies.Hims & Hers Health plans to begin offering new wellness treatments in November, including an unapproved...

When Political Priorities and FDA Science Collide

HHS proposes expanding access to six unapproved peptides despite objections from FDA scientists. This raises questions about regulatory oversight, patient safety, and the distinction between enforcement discretion and drug approval.The Trump administration is moving...

What to Know about FDA’s Revised Peptide Guidance

What Manufacturers Need to Know Seventeen revised draft product-specific guidance documents reflect FDA's evolving scientific and regulatory approach to generic peptide drug development. On July 28, 2026, the U.S. Food and Drug Administration (FDA) published 17...

The Regulatory Dilemma of Experimental Peptides

As demand for experimental peptides grows, a fundamental question confronts federal regulators. Can access to unapproved drug products expand without compromising the standards intended to protect patients? The growing popularity of experimental peptides such as...

FDA Moves Toward New Peptide Compounding Policy

FDA Moves Toward New Peptide Compounding PolicyAgency submits proposed policy change for White House review as HHS signals support for expanded access to experimental peptides Nearly three months after an FDA advisory committee recommended adding six experimental...

Peptides square tile
Pharma square image
Pharma Recalls
Dietary Supplements MDP
Biologics Square Image